EP 157: Bridging genomics, business, and equity in healthcare access with Mark Taylor of LGC Group

The Genetics Podcast

#Science #Natural Sciences #Sano Genetics #Genetics #Precision Medicine #Personalised Medicine #Personalized Medicine #DNA #Gene

36:27

Not many artists actually hail from Tennessee, but the scenic valleys and rolling hills of The Volunteer State are part of Dustin Lynch’s DNA. In this episode of On the Bus, Country Thunder CEO Troy Vollhoffer sits down with Dustin to discuss his journey from playing fraternity parties and weddings across the southeast to being the first country artist with a club residency at the Wynn in Las Vegas. Plus, stick around for our new segment, Thunder Strike, where Troy features upcoming festival performer Riley Green’s hit song “Damn Good Day to Leave” to give you a taste of what’s to come at Country Thunder in 2025.…

год назад 35:40

MP3•Главная эпизода

In this episode, Patrick speaks with Mark Taylor, Head of Strategic Partnerships at LGC Group, about bridging the gap between genomics innovation and equitable healthcare. They discuss Mark's work with the National Institute for Health Research (NIHR), challenges in scaling precision therapies for the NHS, and strategies for engaging underrepresented populations. Additionally, we’re excited to invite you to an in-person meet up for The Genetics Podcast during the ASHG Annual Meeting in Denver, CO! Over the years, we’ve had the honor of speaking with leading voices across science, industry, patient advocacy, and policy. Now, we’re bringing this incredible community together face-to-face. Join us on the evening of Thursday, November 7. To RSVP, visit: https://lu.ma/geneticspodASHG.

211 эпизодов

The Genetics Podcast

EP 157: Bridging genomics, business, and equity in healthcare access with Mark Taylor of LGC Group

The Genetics Podcast

35 subscribers

published год назад

MP3•Главная эпизода

211 эпизодов

#Science #Natural Sciences #Sano Genetics #Genetics #Precision Medicine #Personalised Medicine #Personalized Medicine #DNA #Gene

Все серии

The Genetics Podcast

1
EP 182: Demystifying genetic counseling with Matt Burgess 48:28

15 hours назад48:28

48:28

This week on The Genetics Podcast, Patrick is joined by Matt Burgess, genetic counselor, host of the Demystifying Genetics podcast, and Adjunct Professor at Bay Path University. They discuss the evolution of genetic counseling, ethical challenges in gene therapy, and Matt’s experiences with his podcast. Show Notes: 0:00 Intro to The Genetics Podcast 00:59 Welcome to Matt 02:09 Matt’s run-ins with Olivia Newton John while working at Austin Hospital in Melbourne 04:34 Matt’s background and path to genetic counseling 06:58 The evolution of the field of genetic counseling over time and the role of counselors 12:47 Matt’s work on rare disease AP-4 hereditary spastic paraplegia (AP-4-HSP) and the ethical considerations of gene therapy 20:22 Balancing the needs and expectations of individuals and families in counseling 23:06 Rebranding negative connotations of the word “counseling” 26:58 Memorable episodes from Matt’s podcast Demystifying Genetics 34:31 Differences in genetic counseling and healthcare in the US versus Australia and the UK 40:00 Matt’s current work on writing a novel, starting a company called Rosalind Genetics, and being involved in genetic education 42:47 The potential and drawbacks of AI models in the context of genetic counseling and information 46:46 Closing remarks Find out more Demystifying Genetics ( https://demystifying-genetics.buzzsprout.com/ ) Please consider rating and reviewing us on your chosen podcast listening platform! https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link…

The Genetics Podcast

1
EP 181: Transforming frustration into breakthroughs in gene therapy with Salvador Rico of Encoded Therapeutics 45:30

8 дней назад45:30

45:30

This week on The Genetics Podcast, Patrick is joined by Salvador Rico, Chief Medical Officer at Encoded Therapeutics. They discuss Salvador’s journey into drug development, his work on gene therapy for X-linked myotubular myopathy, and fundamental challenges and exciting advances in the genetics field. Show Notes: 0:00 Intro to The Genetics Podcast 00:59 Welcome to Salvador and how he became involved in drug development 11:01 Frustrations and rewards of the genetics field 13:59 Salvador’s study on gene therapy for patients with X-linked myotubular myopathy (XLMTM) 19:46 Risk of liver issues in gene therapy trials and attempts to mitigate them 24:22 Encoded Therapeutics‘ approach to drug discovery and what motivated Salvador to join the team 27:22 Steps towards therapeutic targeting of gene regulatory elements 30:04 Advantages of different methods for drug delivery 32:31 DNA- versus RNA-based therapy 34:56 Insights from approaches in other fields, including psychiatry 36:35 Considerations for using natural history studies 40:32 Expectations and goals for Encoded Therapeutics’ current and upcoming studies 43:17 Closing remarks Find out more Encoded Therapeutics ( https://encoded.com/ ) Please consider rating and reviewing us on your chosen podcast listening platform! https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link…

The Genetics Podcast

1
EP 180: From a consulting project to a biotech start-up with Leeland Ekstrom of Nashville Bio 41:24

15 дней назад41:24

41:24

This week on The Genetics Podcast, Patrick is joined by Leeland Ekstrom, CEO and co-founder of Nashville Bio. They discuss how Leeland went from being a consultant on a project for Vanderbilt University to a co-founder of a start-up and the unique aspects of NashBio’s clinical and genetic database. Show Notes: 0:00 Intro to The Genetics Podcast 00:59 Welcome to Leeland and the origin story of Nashville Bio 05:13 Process of setting up NashBio’s genome resource with 250K individuals 11:52 How different pharmaceutical companies responded to NashBio’s database and its unique advantages compared to others 17:50 Key priorities for applications of the resource beyond target discovery 20:19 The process of selecting additional gaps that NashBio’s services can fill versus letting others fill them 25:02 Advantages at Vanderbilt Medical Center that facilitated the project and how it can be replicated at other centers 30:32 Immediate and long-term impacts of current NIH funding cuts on biotech and academia 36:43 NashBio’s current major focuses and future goals 39:20 Closing remarks Find out more NashBio ( https://nashbio.com/ ) Press release: Alliance for Genomic Discovery completes 250,000 whole genomes to accelerate drug discovery ( https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=b4b0c901-f8a2-4802-a4ef-b81167e24cfe ) Please consider rating and reviewing us on your chosen podcast listening platform! https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link…

The Genetics Podcast

1
EP 179: Redefining rare disease realities with Sharon Terry of the Genetic Alliance 42:08

22 дня назад42:08

42:08

This week on The Genetics Podcast, Patrick is joined by Sharon Terry, President & CEO of Genetic Alliance. They discuss how Sharon established a layperson-led biobank, her long-term work on rare diseases and patient advocacy, and her program to bring genetic technology to patients in low- to middle-income countries. Show Notes: 0:00 Intro to The Genetics Podcast 00:59 Welcome to Sharon and a discussion of the personal experience with rare disease that started her journey 03:47 Reasons why Sharon decided to establish the first layperson-led biobank 05:34 Challenges with setting up the biobank infrastructure 07:00 Balancing financial factors in a non-profit organization 09:30 Recent patterns and future insight into rare disease drug discovery framework and regulation 15:32 Barriers to widespread collaboration and cooperation in rare disease research, and why it should be approached from a public health perspective 18:12 Background and experiences from the iHope Genetic Health program in low- to middle-income countries 24:44 Sharon’s perspective on current challenges with the Genetic Information Non-discrimination Act 28:49 Sharon’s lessons learned in her patient advocacy and policy work, and her hopes for future legislation 33:04 Sharon’s hopes for improved access to genetic testing and treatment for children in underserved communities 34:34 How Sharon learned about rare diseases and genetics as a “homeschooling mom without a degree” 37:54 Insights into how elements of spirituality can support advocacy work 40:18 Closing remarks Find out more Genetic Alliance ( https://geneticalliance.org/ ) Please consider rating and reviewing us on your chosen podcast listening platform! https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link…

The Genetics Podcast

1
EP 178: Expanding the human proteome to facilitate drug discovery with John Lepore of ProFound Therapeutics 39:37

29 дней назад39:37

39:37

This week on The Genetics Podcast, Patrick is joined by Dr. John Lepore, physician-scientist and CEO of ProFound Therapeutics. They discuss ProFound Tx’s mission to expand the proteome to identify novel drug targets – which resulted in the ProFoundry atlas – and the ways in which John’s diverse experiences inform his approach as a leader. Show Notes: 0:00 Intro to The Genetics Podcast 00:59 Welcome to John 02:01 John’s background at GSK and his transition to drug discovery 05:45 Establishing ProFound Therapeutics to expand the proteome and identify novel drug targets 08:27 Genomic origins of newly-identified proteins and the process of finding them 09:49 Developing the ProFoundry atlas and integrating data across assays 15:27 Different approaches to inferring protein links and association to disease 17:13 Collaboration with Pfizer to find regulators in the context of obesity 18:04 Developing novel antibody-drug conjugates for cancer treatment 20:27 Clarifying causality in proteomic data 21:59 Approaching novel targets while considering industrial and business factors 25:19 John’s background as a cardiologist and how that impacts his current work 27:26 Tips for biotech companies looking to be noticed by pharma for collaborations 30:30 Considerations for investigating new and different therapeutic modalities and techniques 33:39 How John consistently reinforces the translational angle as a business leader 36:24 Closing remarks and future direction for ProFound Therapeutics Find out more ProFound Therapeutics ( https://www.profoundtx.com/ ) Please consider rating and reviewing us on your chosen podcast listening platform! https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link…

The Genetics Podcast

1
EP 177: The vision of Our Future Health with Raghib Ali 43:16

5 weeks назад43:16

43:16

This week on The Genetics Podcast, Patrick is joined by Raghib Ali, CEO, CMO, and Principal Investigator of Our Future Health UK. As a clinical epidemiologist with a passion for reducing health inequalities, Raghib offers fresh insights into the priorities, challenges, and transformative impact of the groundbreaking genomics initiative, Our Future Health. Show Notes: 0:00 Intro to The Genetics Podcast 01:00 Welcome to Raghib and background on Our Future Health (OFH) 03:57 Diseases that are a priority for OFH or are likely to benefit from its impact 06:07 Challenges and opportunities for implementing change in the National Health Service (NHS), a partner of OFH, based on study findings 09:20 Factors that contributed to the rapid recruitment of participants to OFH 14:12 Efforts to ensure diversity of OFH participants and facilitate accessibility for all 16:35 Why OFH chose to use arrays for genomic profiling 18:57 Navigating the obstacles and opportunities in public and private partners 22:28 Strengths and weaknesses of the medical record system in the UK 25:54 Efforts to rapidly provide results from OFH and integrating other datasets and techniques in the future 28:43 Raghib’s unique educational and training journey 31:49 The importance of evaluating components beyond genetics for a full picture of health 33:28 Aims and findings of the first prospective cohort study in the UAE 35:26 The potential contribution of epigenetic inheritance to disease risk 37:43 How Raghib overcame adversity early in life 40:56 Closing remarks Find out more Our Future Health ( https://ourfuturehealth.org.uk/ ) Please consider rating and reviewing us on your chosen podcast listening platform! https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link…

The Genetics Podcast

1
EP 176: Hunting rare kidney disease mutations with Anthony Bleyer of Wake Forest and Stan Kmoch of Charles University 38:24

6 weeks назад38:24

38:24

This week on The Genetics Podcast, we’re celebrating Rare Disease Day with a very special episode. Patrick is joined by clinical nephrologist Anthony Bleyer and geneticist Stan Kmoch to discuss how their decade-long international collaboration has uncovered genetic mutations in families with rare inherited kidney diseases – including Patrick’s. Show Notes: 0:00 Intro to The Genetics Podcast 00:59 Welcome to Anthony and Stan 02:05 The origin story for Anthony and Stan’s long-distance collaboration 06:55 Stan’s background in metabolic disorders and sequencing techniques 11:09 Common genetic culprits and barriers to identifying mutations that cause kidney disease 14:01 Background and findings from Anthony and Stan’s ApoA4 study 23:54 Potential therapeutic avenues based on the ApoA4 study 26:49 Current and future focuses for characterizing diseases in families 30:42 Working with collaborators internationally to access large databases and registries 33:05 Innovative transplant methods, including genetically-modified pig kidneys 36:36 Closing remarks and a heartfelt thank you to researchers and families driving rare disease research Find out more Latest study: https://doi.org/10.1016/j.kint.2023.11.021 Please consider rating and reviewing us on your chosen podcast listening platform! https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link…

The Genetics Podcast

1
EP 175: Pioneering treatment for stop codon disease using tRNA with Michelle Werner of Alltrna 44:45

7 weeks назад44:45

44:45

This week on The Genetics Podcast, Patrick is joined by Michelle Werner, CEO at Alltrna and CEO/Partner at Flagship Pioneering. They discuss Alltrna’s promising findings from its first preclinical study on using tRNA to rescue stop codon disease, the strategic use of basket trials, and more! Show Notes: 0:00 Intro to The Genetics Podcast 01:00 Welcome to Michelle 02:13 Overview of Alltrna’s aims and the advantages of using tRNA to tackle stop codon disease 5:27 Using basket trials for genetic diseases 08:03 Highlights from Alltrna’s first preclinical study using tRNA to restore protein production to clinically meaningful levels in methylmalonic acidemia (MMA) and phenylketonuria (PKU) 14:02 Considerations in delivery techniques and Alltrna’s use of nanoparticles 19:22 Stability of tRNA and how engineered tRNAs are recognized in vivo 23:12 Strategic design of basket trials and diseases that are covered 26:16 Adaptive trial design in the rare genetic disease setting 28:15 Michelle’s experience with regulatory organizations on new approaches to trial design 32:14 Insights from spearheading Alltrna and Flagship Pioneering’s innovative approaches 37:26 Michelle’s lessons from working in big pharma versus a small biotech start-up 40:50 Closing remarks and a call for collaborators Find out more Alltrna ( https://www.alltrna.com/ ) Please consider rating and reviewing us on your chosen podcast listening platform! https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link…

The Genetics Podcast

1
EP 174: Decentralized science and reducing the cost of gene therapies with Jocelynn Pearl of the TAM Center 46:08

8 weeks назад46:08

46:08

On this week’s episode of The Genetics Podcast, we’re joined by Jocelynn Pearl, Director of Cancer Cell Therapy at the TAM Center, host of the Lady Scientist Podcast and Co-Founder of LabDAO. Patrick and Jocelynn discuss her move to Mexico to help accelerate the development of new cancer therapies, harnessing the power and potential of decentralized science, and overcoming sky-high gene therapy costs to increase accessibility for patients. Show Notes: 0:00 Intro to The Genetics Podcast 01:00 Welcome to Jocelynn 02:03 Jocelynn’s past work at The Institute for Systems Biology 04:55 How Jocelynn approached her transition to biotech from the world of academia 10:14 Exploring decentralized science, including how it works and Jocelynn’s involvement to date 15:54 What a Decentralized Autonomous Organisation (DAO) is and how this type of organizational structure supports scientific development 22:45 The “fast grant” surge and other non-traditional funding methods 28:00 Hosting the Lady Scientist Podcast and some of Jocelynn’s favorite moments 32:43 Jocelynn’s move to Mexico to serve as Director of Cancer Cell Therapy at the TAM Center 36:12 The biggest differences between building out drug development programs in Mexico and the US 38:31 Regulatory differences between countries in the context of stem cell therapies 42:48 The advantages for cancer therapeutic development in Jocelynn’s current environment 46:20 Driving down the costs of gene therapies and the impact on accessibility 48:09 Closing remarks Find out more LabDAO: https://www.lab.bio/ Please consider rating and reviewing us on your chosen podcast listening platform! https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj…

The Genetics Podcast

1
EP 173: Tackling genetic cardiomyopathy from the bed to the bench with Eric Adler of Lexeo Therapeutics and UCSD 41:11

9 weeks назад41:11

41:11

Summary: This week on The Genetics Podcast, Patrick is joined by Eric Adler, Chief Medical Officer and Head of Research at Lexeo Therapeutics and Professor of Medicine at University of California San Diego. Eric shares his experience with genetic cardiomyopathy and his work on gene therapy for Danon disease, drawing from both clinical and research perspectives. Additionally, he explores the evolution of the field and the broader challenges faced by cardiovascular patients. Show Notes: 0:00 Intro to The Genetics Podcast 01:00 Welcome to Eric and his efforts in cardiomyopathy at the bench and bedside 03:32 How modeling genetic diseases using pluripotent stem cells lead Eric to studying Danon disease 04:50 Pivoting from basic to translational research using adeno-associated viruses (AAV)-based gene therapy 07:58 Uncovering genetic cardiomyopathies that were misdiagnosed as idiopathic cardiomyopathy 09:55 Treatment, screening, and penetrance of Danon disease 12:30 Recent successes and remaining challenges in cardiovascular disease 19:47 Battling distrust in the medical profession 21:55 Preventative therapy using APOE2 for patients at risk of early Alzheimer’s 25:15 Motivations behind and advantages of Eric’s patient-centered approach to therapeutics 27:24 Balancing regulatory requirements for protocols versus patient needs 29:49 The importance of committed clinical partners for successful trial execution 36:08 Eric’s passion for cooking and how he won a cooking competition 39:02 Closing remarks and Lexeo Therapeutics’ aims for 2025 Find out more Lexeo Therapeutics ( https://www.lexeotx.com/ ) Please consider rating and reviewing us on your chosen podcast listening platform! https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link…

The Genetics Podcast

1
EP 172: Racial health disparities in genetic testing and breast cancer treatment with Dr. Versha Pleasant of University of Michigan 48:48

10 weeks назад48:48

48:48

This week on The Genetics Podcast, Patrick is joined by Versha Pleasant, Clinical Assistant Professor in the Department of Obstetrics and Gynecology, University of Michigan and Director of the Cancer Genetics and Breast Health Clinic at Von Voigtlander Women’s Hospital. They discuss ongoing disparities in healthcare, in particular why black women in the US have a 40% higher chance of dying from breast cancer than white women, the impact of the US Educate Act on equality, diversity and inclusion education, and much more. 00:00:00 – Intro to The Genetics Podcast 00:01:52 – Welcome to Versha 00:03:22 – How black women have a 40% higher chance of mortality from breast cancer than white women, and the biggest drivers of this disparity 00:07:09 – Multifaceted approaches to addressing disparities 00:09:10 – Racial health duplicity and increasing access to genetic testing and mammography for black women 00:13:51 – The challenges of using precision medicine to stratify risk in black communities and historical harms in US medical research 00:14:29 – How to design for inclusive studies that effectively represent communities of colour 00:16:13 – Considering universal genetic testing and counseling for black women 00:21:24 – The logistics of making universal testing a reality, and the importance of community education and trust building 00:27:18 – What Versha is focused on next and the big topics she wants to tackle 00:33:24 – The role of community education and diversifying modes of communication for knowledge sharing 00:34:36 – Versha’s perspectives on the US Educate Act and the impact it could have on what doctors of the future are taught 00:40:52 – Versha’s advice to people who would like to pursue a similar career in medicine 00:43:28 – Where Patrick sees genetics evolving in the next ten years and his vision for the future of The Genetics Podcast 00:47:39 – Closing remarks Find out more Universal Genetic Counseling and Testing for Black Women: A Risk-Stratified Approach to Addressing Breast Cancer Disparities: https://www.clinical-breast-cancer.com/article/S1526-8209(24)00338-0/fulltext Please consider rating and reviewing us on your chosen podcast listening platform! https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link…

The Genetics Podcast

1
EP 171: The past, present, and future of long-read sequencing with Jonathon Hill of Wasatch Biolabs 35:13

11 weeks назад35:13

35:13

This week on The Genetics Podcast, Patrick is joined by Jonathon Hill, associate professor at Brigham Young University and co-founder and VP of Wasatch Biolabs. Jonathan and Patrick discuss the power of long-read sequencing, how Wasatch Biolabs was created, and how Jonathon has fostered valuable collaborations between academic labs and Wasatch Biolabs.…

The Genetics Podcast

1
EP 170: Pan-European collaboration and dementia research with Angela Bradshaw, from Alzheimer Europe 42:25

12 weeks назад42:25

42:25

This week on The Genetics Podcast, Patrick is joined by Angela Bradshaw, Director for Research at Alzheimer Europe and honorary lecturer at the University of Glasgow. Patrick and Angela discuss how Alzheimer Europe partners in and support pan-European dementia research, the enormous heterogeneity of dementia and Alzheimer’s disease, the future of potential new gene therapies, and the critical role of advocacy organizations for patient communities.…

The Genetics Podcast

1
EP 169: Common variants in rare neurological diseases with Hilary Martin of the Wellcome Sanger Institute 45:39

13 weeks назад45:39

45:39

This week on The Genetics Podcast, we’re joined by Hilary Martin, Group Leader in Human Genetics at the world-renowned Wellcome Sanger Institute. Hilary and Patrick discuss her group’s work on neurodevelopmental conditions, the role of common genetic variants in rare disease, and how to untangle the impact of direct and indirect genetic influences on various traits. Find out more Nature paper: Examining the role of common variants in rare neurodevelopmental conditions https://www.nature.com/articles/s41586-024-08217-y Genes and Health Project https://www.genesandhealth.org…

The Genetics Podcast

1
EP 168: A world-first in RNA medicines with Erik Ingelsson, Chief Scientific Officer at Wave Life Sciences 37:54

14 weeks назад37:54